A Phase 2 clinical trial investigating evofosfamide in combination with both CTLA-4 and PD-1 blockade in patients with castration-resistant prostate cancer (CRPC), pancreatic ductal adenocarcinoma (PDAC) and HPV-negative head and neck cancer (HNSCC)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evofosfamide (Primary)
Indications Head and neck cancer; Pancreatic cancer; Prostate cancer
Focus Therapeutic Use

Most Recent Events

09 Feb 2022 According to an IMMUNOGENESIS media release, this trial is expected to begin in 2022.
17 Dec 2020 New trial record
09 Dec 2020 According to an IMMUNOGENESIS media release, this trial is supported by data from a Phase 1 trial (NCT03098160), and this trial will be led by David S. Hong, M.D., Professor of Investigational Cancer Therapeutics at MD Anderson.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight